In treatment-naïve MRCC patients receiving IFN-α, six (2%) venous thromboembolic events occurred; one patient (< 1%) experienced a Grade 3 DVT and five patients (1%) had pulmonary embolisms, one with Grade 1 and four with Grade 4.